Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCPNASDAQ:EARSNASDAQ:NRSNNASDAQ:PHIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$1.55+2.0%$1.53$1.12▼$3.26N/A2.1526,433 shs9,693 shsEARSAuris Medical$0.30$2.88$0.73▼$6.60$3.43M1.173.10 million shs830,271 shsNRSNNeuroSense Therapeutics$1.98-10.0%$1.56$0.51▼$2.60$30.07M1.62279,210 shs610,254 shsPHIOPhio Pharmaceuticals$2.21+1.8%$2.13$0.97▼$9.79$10.41M0.842.43 million shs201,781 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma+1.97%0.00%+9.15%+4.73%-36.48%EARSAuris Medical0.00%0.00%0.00%0.00%-72.97%NRSNNeuroSense Therapeutics-10.00%-19.18%+30.26%+98.99%+132.50%PHIOPhio Pharmaceuticals+1.84%-6.36%+29.24%+71.32%-64.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOCPCocrystal Pharma2.2688 of 5 stars3.53.00.00.02.21.70.0EARSAuris MedicalN/AN/AN/AN/AN/AN/AN/AN/ANRSNNeuroSense Therapeutics2.5667 of 5 stars3.53.00.00.03.31.70.0PHIOPhio Pharmaceuticals3.5844 of 5 stars3.55.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCPCocrystal Pharma 3.00Buy$6.00287.10% UpsideEARSAuris Medical 0.00N/AN/AN/ANRSNNeuroSense Therapeutics 3.00Buy$14.00607.07% UpsidePHIOPhio Pharmaceuticals 3.00Buy$14.00533.48% UpsideCurrent Analyst Ratings BreakdownLatest EARS, NRSN, COCP, and PHIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.006/20/2025COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.006/5/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/12/2025NRSNNeuroSense TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCPCocrystal PharmaN/AN/AN/AN/A$0.94 per shareN/AEARSAuris MedicalN/AN/AN/AN/A$1.57 per shareN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/A$0.19 per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$0.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCPCocrystal Pharma-$17.50M-$1.57N/AN/AN/AN/A-135.12%-102.38%8/13/2025 (Estimated)EARSAuris Medical-$8.75MN/A0.00∞N/AN/AN/AN/AN/ANRSNNeuroSense Therapeutics-$10.21M-$0.54N/A∞N/AN/AN/A-445.40%N/APHIOPhio Pharmaceuticals-$7.15M-$10.92N/A0.59N/AN/A-105.65%-89.19%8/13/2025 (Estimated)Latest EARS, NRSN, COCP, and PHIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025COCPCocrystal Pharma-$0.52-$0.23+$0.29-$0.23N/AN/A4/7/2025Q4 2024NRSNNeuroSense Therapeutics-$0.12-$0.06+$0.06-$0.06N/AN/A3/27/2025Q4 2024COCPCocrystal Pharma-$0.55-$0.32+$0.23-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOCPCocrystal PharmaN/AN/AN/AN/AN/AEARSAuris MedicalN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCPCocrystal PharmaN/A4.574.57EARSAuris MedicalN/A3.833.83NRSNNeuroSense TherapeuticsN/A2.212.21PHIOPhio PharmaceuticalsN/A10.5810.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCPCocrystal Pharma6.72%EARSAuris Medical6.03%NRSNNeuroSense Therapeutics1.04%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipCOCPCocrystal Pharma28.14%EARSAuris MedicalN/ANRSNNeuroSense Therapeutics27.40%PHIOPhio Pharmaceuticals0.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCPCocrystal Pharma10N/AN/ANot OptionableEARSAuris Medical132,20011.42 millionN/ANot OptionableNRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionablePHIOPhio Pharmaceuticals104.80 million4.77 millionNot OptionableEARS, NRSN, COCP, and PHIO HeadlinesRecent News About These CompaniesHC Wainwright Reiterates "Buy" Rating for Phio Pharmaceuticals (NASDAQ:PHIO)June 26 at 3:07 AM | americanbankingnews.comPhio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation CohortJune 25 at 7:45 AM | newsfilecorp.comNPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesJune 24 at 7:45 AM | newsfilecorp.comNPhio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA PortfolioJune 6, 2025 | newsfilecorp.comNBest Value Stocks to Buy for May 28thMay 28, 2025 | zacks.comNew Strong Buy Stocks for May 28thMay 28, 2025 | zacks.comPhio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor ConferenceMay 19, 2025 | newsfilecorp.comNPhio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical TrialMay 7, 2025 | finanznachrichten.dePhio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical TrialMay 7, 2025 | newsfilecorp.comNPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMay 1, 2025 | newsfilecorp.comNBest Momentum Stocks to Buy for April 23rdApril 23, 2025 | zacks.comBest Value Stocks to Buy for April 23rdApril 23, 2025 | zacks.comPhio Pharmaceuticals Corp. Common StockApril 12, 2025 | fxempire.comFPhio Pharmaceuticals announces Safety Monitoring Committee recommendation to advance INTASYL PH-762 skin cancer studyApril 12, 2025 | pharmabiz.comPPhio advances skin cancer treatment with successful trialApril 11, 2025 | uk.investing.comPHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next DoseApril 10, 2025 | zacks.comThis Biotech Is Ripping Following Phase 1b Trial AnnouncementApril 9, 2025 | msn.comPhio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s ThrilledApril 9, 2025 | msn.comPhio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation CohortApril 9, 2025 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPalantir Defies Bears, Leads S&P 500 in 2025By Chris Markoch | June 16, 2025View Palantir Defies Bears, Leads S&P 500 in 20253 Tech Focused ETFs to Watch as the Market Nears All-Time HighsBy Ryan Hasson | June 11, 2025View 3 Tech Focused ETFs to Watch as the Market Nears All-Time HighsAST SpaceMobile's Signal Strengthens as Stock Nears OrbitBy Jeffrey Neal Johnson | June 25, 2025View AST SpaceMobile's Signal Strengthens as Stock Nears OrbitFastenal Stock After Split: Poised for 5 More Years of GainsBy Jeffrey Neal Johnson | June 13, 2025View Fastenal Stock After Split: Poised for 5 More Years of GainsIs Meta Plotting a Stablecoin Comeback Years After Libra's Flop?By Leo Miller | June 5, 2025View Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop?EARS, NRSN, COCP, and PHIO Company DescriptionsCocrystal Pharma NASDAQ:COCP$1.55 +0.03 (+1.97%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.53 -0.02 (-1.55%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Auris Medical NASDAQ:EARSAuris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.NeuroSense Therapeutics NASDAQ:NRSN$1.98 -0.22 (-10.00%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.00 +0.02 (+1.26%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Phio Pharmaceuticals NASDAQ:PHIO$2.21 +0.04 (+1.84%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.21 +0.00 (+0.18%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
